Maxcyte, INC Form 4 insider transactions

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Director Cynthia Collins reports acquisition of MaxCyte stock and options, including restricted stock units and stock options, in a recent Form 4 filing.

Director Stanley Erck exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged 10b5-1 trading plan.

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Chief Commercial Officer Ali Soleymannezhad of MaxCyte, Inc. reports the acquisition of restricted stock units and stock options.

Director Stanley C. Erck of MaxCyte, Inc. exercised stock options and sold shares of common stock on September 3rd and 4th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. (MXCT) on August 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Thomas M. Ross, EVP of Global Sales at MaxCyte, Inc., exercised stock options and sold shares of common stock on August 1st and 2nd, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

Thomas M. Ross, EVP of Global Sales at MaxCyte, Inc., executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

John Johnston, a director at MaxCyte, Inc., executed option exercises and stock sales on June 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Thomas M. Ross, EVP of Global Sales at MaxCyte, Inc., exercised stock options and sold shares of common stock according to a pre-arranged Rule 10b5-1 trading plan.

Director Art Mandell acquired shares and stock options in MaxCyte, Inc. on June 11, 2024, according to a Form 4 filing.

Director Richard Douglas acquired 21,367 shares of common stock (restricted stock units) and stock options for 40,701 shares of MaxCyte, Inc. on June 11, 2024, as part of the company's Equity Grant Policy for non-employee directors.

Director Rekha Hemrajani of MaxCyte, Inc. receives stock options and restricted stock units as part of the company's Equity Grant Policy for non-employee directors.

Director Stanley C Erck received an annual equity grant from MaxCyte, Inc. consisting of restricted stock units and stock options.

Director Yasir B. Al-Wakeel reports acquisition of 21,367 shares of common stock and 40,701 stock options in MaxCyte, Inc.

Director John Johnston acquired shares and options in MaxCyte, Inc. as part of the company's Equity Grant Policy for non-employee directors.

Director Patrick J. Balthrop acquired 21,367 shares of common stock and 40,701 stock options in MaxCyte, Inc. on June 11, 2024, as part of an annual equity grant.

Director William W. Brooke reports acquisition of MaxCyte shares and stock options as part of an annual equity grant.

MaxCyte's President and CEO, Maher Masoud, recently acquired a significant number of company shares through multiple transactions.

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.

EVP of Global Sales & Marketing at MaxCyte, Thomas M. Ross, reports acquisition of common stock and stock options.

David I. Sandoval, General Counsel of MaxCyte, Inc., reports acquisition of common stock and stock options.

Douglas Swirsky, CFO of MaxCyte, Inc., reports acquisition of common stock and stock options.

Director John Johnston exercised stock options and sold shares of MaxCyte, Inc. under a pre-arranged Rule 10b5-1 trading plan.